SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the expansion of its leadership team with three promotions: Mollie Leoni, M.D., to Senior Vice President, Clinical Development, Pete De Spain to Senior Vice President, Investor Relations and Corporate Communications, and Tom Doyle to Senior Vice President, Finance and Accounting. Mr. Doyle will also assume the role of Kura’s Principal Accounting Officer from Marc Grasso, M.D., who will be stepping down as the Company’s Chief Financial Officer and Chief Business Officer, effective February 4, 2022, to pursue opportunities closer to his family. Dr. Grasso will serve in an advisory capacity during the transition.
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
